Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

92
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
92

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.

Communications medicine·2026
Same authorSame journal

[18F]F-DOPA and [18F]F-FDG PET/CT for staging advanced medullary thyroid cancer.

Annales d'endocrinologie·2026
Same author

[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.

The Lancet. Oncology·2026
Same author

Impact of the French ENDOCAN-COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Management of Hemodialyzed Patients Treated with Radioactive Iodine for Thyroid Cancer: How Could We Improve It? Tracks from the Lille Experience.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Bone phenotype in familial partial lipodystrophy type 2: Insulin resistance and sclerostin.

Diabetes & metabolism·2026

Related Experiment Video

Updated: May 12, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.5K

ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer.

Hélène Lasolle1, Christine Do Cao2, Livia Lamartina3

  • 1Department of Endocrinology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Université Lyon1, Lyon, France.

Annales D'Endocrinologie
|April 27, 2025
PubMed
Summary

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor often linked to RET mutations. Advances in targeted therapies offer new hope for managing refractory MTC, requiring personalized treatment strategies.

Area of Science:

  • Oncology
  • Endocrinology
  • Genetics

Background:

  • Medullary thyroid carcinoma (MTC) comprises 2-4% of thyroid cancers.
Keywords:
GeneticsMedullary thyroid carcinomaProto-oncogene RETRefractory thyroid cancerTargeted therapy

More Related Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

462
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.0K

Related Experiment Videos

Last Updated: May 12, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.5K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

462
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.0K
  • MTC is a neuroendocrine tumor frequently associated with RET proto-oncogene mutations (germline in 20-25%, somatic in 70-80% of metastatic cases).
  • Locally advanced and metastatic MTC are termed 'refractory', presenting a variable clinical behavior and challenging prognosis.